Gnosis Pay Reviews Security Incident: Vulnerability Caused by Signature Verification Logic Flaw, Now Fixed
Foresight News reported that Gnosis Pay released a review report on the June 1 security incident, disclosing that the root cause of the vulnerability was a flaw in the ERC-1271 signature verification logic within the Zodiac module: the system only read the contract's return result without checking whether the call had actually succeeded. Attackers exploited this by deploying a contract designed to intentionally fail but still return a "valid" indicator, thereby forging authorization and withdrawing funds from accounts they did not own. This vulnerability was introduced with version 3.4.0 of the Zodiac code in October 2023 and was fixed on June 5. According to the report, the attackers stole approximately 1.5 million US dollars, affecting 5,281 wallets, including about 641,000 US dollars in GNO, about 453,000 US dollars in EURe, and about 399,000 US dollars in USDC.e; an additional 300,000 US dollars is locked in inaccessible accounts, and the team is exploring recovery options. Gnosis Pay stated that they will expand their security team, introduce external audits, broaden the scope of smart contract audits, and have completed a comprehensive product rebuild (v2) to enhance security response capabilities.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Terranor Group schedules Q3 results presentation
WTI crude oil futures prices fall by more than 1%

Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
